Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nang Kuang Pharmaceutical CoTPE:1752 -1.10%88 EV-to-FCF is 18.99 as of Jul. 14, 2026, which is 16% below its 10-year median of 22.52. GuruFocus rates TPE:1752 with a GF Score™ of 88/100 and a GF Value™ of NT$46.62 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 414 Medical Devices & Instruments companies, Nang Kuang Pharmaceutical Co ranks better than 60.63% on this metric.
The historical rank and industry rank for Nang Kuang Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
TPE:1752'
s EV-to-FCF Range Over the Past 10 Years
Min: -79.51 Med: 22.52 Max: 4156.82
Current: 19.24
During the past 13 years, the highest EV-to-FCF of Nang Kuang Pharmaceutical Co was 4156.82. The lowest was -79.51. And the median was 22.52.
TPE:1752's EV-to-FCF is ranked better than 60.63% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.445
vs TPE:1752: 19.24
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nang Kuang Pharmaceutical Co (TPE:1752) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nang Kuang Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Nang Kuang Pharmaceutical Co's share price for today is NT$31.35.
Nang Kuang Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.400.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Nang Kuang Pharmaceutical Co EV-to-FCF Related Terms
Nang Kuang Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Nang Kuang Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nang Kuang Pharmaceutical Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nang Kuang Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Nang Kuang Pharmaceutical Co's EV-to-FCF falls into.
Nang Kuang Pharmaceutical Co's current Enterprise Value is NT$3,477 Mil.
Nang Kuang Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$183 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nang Kuang Pharmaceutical Co (TPE:1752) has a EV-to-FCF of 18.99 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nang Kuang Pharmaceutical Co and its competitors. This is 16% below median its historical median of 22.52. According to the industry distribution chart, Nang Kuang Pharmaceutical Co ranks #163 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 39.4%.
Is Nang Kuang Pharmaceutical Co's EV-to-FCF too high?
Nang Kuang Pharmaceutical Co's current EV-to-FCF of 18.99 is 16% below median its 10-year median of 22.52. The Medical Devices & Instruments industry median EV-to-FCF is 23.45. Nang Kuang Pharmaceutical Co's value of 18.99 is 19% below this industry median. Based on the distribution chart, Nang Kuang Pharmaceutical Co ranks #163 out of 414 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nang Kuang Pharmaceutical Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nang Kuang Pharmaceutical Co's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nang Kuang Pharmaceutical Co ranks #163 out of 414 companies for EV-to-FCF. This puts Nang Kuang Pharmaceutical Co in the upper half of its industry. The industry median EV-to-FCF is 23.45. Nang Kuang Pharmaceutical Co's value of 18.99 is 19% below this benchmark. While the company's 10-year median is 22.52 vs. the industry median of 23.45, Nang Kuang Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.45, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nang Kuang Pharmaceutical Co's current EV-to-FCF of 18.99 is 19% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nang Kuang Pharmaceutical Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nang Kuang Pharmaceutical Co's current EV-to-FCF is 18.99, which is 16% below median its own 10-year median of 22.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nang Kuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co (TPE:1752) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$46.62, compared to a current price of NT$31.35 — trading 32.8% below its estimated fair value. The current EV-to-FCF is 18.99, which is 16% below median its 10-year median of 22.52 and 19% below the Medical Devices & Instruments industry median of 23.45. Nang Kuang Pharmaceutical Co's overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Nang Kuang Pharmaceutical Co (TPE:1752), the current EV-to-FCF is 18.99 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nang Kuang Pharmaceutical Co (TPE:1752) Overvalued in 2026?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$31.35 is trading 32.8% below its estimated GF Value™ of NT$46.62.
GuruFocus considers Nang Kuang Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for TPE:1752:
EV-to-FCF: 18.99 (16% below median its 10-year median of 22.52)
GF Value™: NT$46.62 vs. price of NT$31.35 (32.8% below fair value)
Industry Position: 19% below the Medical Devices & Instruments median (#163 of 414)
No single metric tells the full story. See the TPE:1752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nang Kuang Pharmaceutical Co Ltd is a Taiwan-based company, its subsidiaries are engaged in the manufacture, processing, and trading, and import and export of pharmaceuticals and medical devices. Its products are Cardiovascular system medications, Gastrointestinal medications, Nervous system drugs, Nutrition and Metabolism, Hospital infusion solution, blood products, Anticancer immunomodulators, Musculoskeletal system, and Others. Geographically, the company operates in Taiwan, China, Japan, the USA, and Other countries.
88GF Score
Get the complete analysis for TPE:1752
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1752 has been successfully added to your 
